深交所上市公司定期现场检查报告 | 保荐人名称：中信建投证券股份有限公司 上市公司简称：金凯生科 | | | | | --- | --- | --- | --- | | 保荐代表人姓名：逯金才 联系电话：010-5605 | 2488 | | | | 保荐代表人姓名：张林 联系电话：010-5605 | 1430 | | | | 现场检查人员姓名：逯金才 | | | | | 现场检查对应期间：2025 年度 | | | | | 现场检查时间：2026 年 3 月 16 日-3 月 17 日 | | | | | 一、现场检查事项 | 现场检查意见 | | | | （一）公司治理 | 是 | 否 | 不适用 | | 现场检查手段（包括但不限于本指引第三十三条所列）：查阅公司章程、公司治理制度以及股东会、董 | | | | | 事会会议资料、信息披露文件等 | | | | | 1.公司章程和公司治理制度是否完备、合规 | √ | | | | 2.公司章程和股东会、董事会规则是否得到有效执行 | √ | | | | 3.股东会、董事会会议记录是否完整，时间、地点、出席人 | √ | | | | 员及会议内容等要件是否 ...

证券代码：301509 证券简称：金凯生科 公告编号：2026-002 金凯（辽宁）生命科技股份有限公司 关于股东减持股份计划期间届满暨减持结果的公告 股东启鹭（厦门）股权投资合伙企业（有限合伙）、青岛青松创业投资集团 有限公司－青岛松凯创业投资企业（有限合伙）、蓝色经济区产业投资基金（有 限合伙）保证向本公司提供的信息内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 金凯（辽宁）生命科技股份有限公司（以下简称"公司"）于近日分别收到股东 启鹭（厦门）股权投资合伙企业（有限合伙）（以下简称"启鹭投资"）、青岛青松 创业投资集团有限公司－青岛松凯创业投资企业（有限合伙）（以下简称"青松投 资"）、蓝色经济区产业投资基金（有限合伙）（以下简称"蓝区基金"）提交的 《关于减持金凯（辽宁）生命科技股份有限公司股份计划期间届满暨减持结果告知 函》，截至本报告披露日，前述股东本次减持计划期限届满。现将有关情况公告如下： 一、股东减持情况 （一）启鹭投资 1、减持股份来源：首次公开发行前持有的公司股份（含该等股份上市后资本公 积金转增股本取得的 ...

Core Viewpoint - The company, Jinkai (Liaoning) Life Science Technology Co., Ltd., specializes in providing custom development and production services for small molecule drug intermediates and a small amount of raw materials for global pharmaceutical companies, with a focus on fluorinated and non-fluorinated CDMO businesses [2][8]. Group 1: Business Overview - The main business involves providing small molecule drug intermediates and limited raw materials for new drug development projects for well-known pharmaceutical companies globally [2][8]. - The company has a significant focus on fluorinated CDMO services, including specialized fluorinated agents and other fluorination processes [3][8]. - As of the 2024 annual report, overseas revenue accounted for 61.18% of total revenue, benefiting from the depreciation of the RMB [4]. Group 2: Financial Performance - For the period from January to September 2025, the company achieved a revenue of 488 million yuan, representing a year-on-year growth of 25.96%, and a net profit attributable to shareholders of 103 million yuan, reflecting a substantial increase of 163.24% [8]. - The company has distributed a total of 117 million yuan in dividends since its A-share listing [9]. Group 3: Market Activity - On February 27, the company's stock price fell by 1.85%, with a trading volume of 140 million yuan and a turnover rate of 6.30%, resulting in a total market capitalization of 4.724 billion yuan [1]. - The stock has seen a net outflow of 15.7573 million yuan from major investors today, with a ranking of 49 out of 52 in its industry, indicating a trend of reduced holdings by major funds over the past three days [5][6]. Group 4: Technical Analysis - The average trading cost of the stock is 38.85 yuan, with the stock price approaching a resistance level of 39.30 yuan, suggesting potential for a price correction if it fails to break through this level [7].

Group 1 - The core point of the article is that Jinkaishengke has reported its number of shareholders as of February 13, 2026, which stands at 14,635 households [2]

Summary of Key Points Core Viewpoint - On February 13, Jin Kai Biotechnology executed a block trade of 785,800 shares, amounting to 28.1867 million yuan, which represented 10.79% of the total trading volume for the day. The transaction price was 35.87 yuan, reflecting a discount of 10.01% compared to the market closing price of 39.86 yuan [1]. Group 1: Trading Details - The block trade involved multiple transactions with a total volume of 785,800 shares at a price of 35.87 yuan per share [2]. - The total transaction value was 28.1867 million yuan, indicating significant trading activity for Jin Kai Biotechnology on that day [1][2]. - The trade was executed at a discount of 10.01% compared to the closing price, suggesting potential investor interest at a lower price point [1]. Group 2: Buyer and Seller Information - The buyers included various brokerage firms such as China Merchants Securities and institutional investors, indicating a mix of retail and institutional participation in the trade [2]. - The selling side was primarily represented by China Zhongjin Wealth Securities, highlighting the role of this firm in the transaction [2]. - The presence of institutional buyers suggests confidence in the stock despite the discount, which may indicate a strategic investment approach [2].

Core Viewpoint - The company, Jinkai (Liaoning) Life Science Technology Co., Ltd., specializes in providing custom development and production services for small molecule drug intermediates and a small amount of raw materials for global pharmaceutical companies, with a focus on fluorinated and non-fluorinated CDMO businesses [2][8]. Group 1: Business Overview - The main products of the company include fluorinated CDMO services and non-fluorinated CDMO services [2]. - The company has a significant project involving the production of intermediates for Semaglutide oral formulations, which is part of its fundraising projects [2][3]. - As of the 2024 annual report, overseas revenue accounted for 61.18% of total revenue, benefiting from the depreciation of the RMB [4]. Group 2: Financial Performance - For the period from January to September 2025, the company achieved a revenue of 488 million yuan, representing a year-on-year growth of 25.96%, and a net profit attributable to shareholders of 103 million yuan, with a remarkable year-on-year increase of 163.24% [8]. - The company has distributed a total of 117 million yuan in dividends since its A-share listing [9]. Group 3: Market Activity - On February 12, the company's stock price decreased by 0.21%, with a trading volume of 93.35 million yuan and a turnover rate of 4.24%, resulting in a total market capitalization of 4.659 billion yuan [1]. - The stock has seen a net outflow of 4.177 million yuan from major investors today, with a ranking of 31 out of 52 in its industry [5][6].

Core Viewpoint - The company, Jinkai Biotechnology (301509), is committed to aligning its production capacity with market information and customer demand, ensuring that key projects meet capacity requirements [1] Group 1 - The company will reasonably plan and arrange production capacity based on market information and customer needs [1] - Specific project information and capacity details will be disclosed in the company's regular reports and other public disclosures [1]

Core Viewpoint - The company Jin Kai Sheng Ke (301509.SZ) has clarified that it does not currently have any products related to Eli Lilly's weight loss medication [1] Group 1 - The company stated that the patent protection for original drug manufacturers typically involves multiple mechanisms, including compound patents, formulation and composition patents, and medical use patents [1] - The impact of the expiration of a single compound patent is currently difficult to predict accurately [1] - The company will continue to monitor relevant changes in the patent landscape [1]

Summary of Key Points Core Viewpoint - On February 6, a block trade of 682,000 shares of Jinkai Biotechnology was executed at a price of 35.43 yuan, representing a discount of 10.01% compared to the market closing price of 39.37 yuan, with a total transaction value of 24.16 million yuan, accounting for 5.48% of the total trading volume for the day [1]. Group 1: Transaction Details - The block trade involved a total of 682,000 shares at a price of 35.43 yuan per share [1]. - The total transaction amount was 24.16 million yuan, which is approximately 3.67 million USD [1]. - The transaction represented 5.48% of the total trading volume on that day [1]. Group 2: Price Comparison - The executed price of 35.43 yuan was 10.01% lower than the market closing price of 39.37 yuan [1].

Group 1 - The core transaction involved 57,000 shares of Jinkai Biotechnology, with a total transaction value of 2.0235 million yuan, representing 0.5% of the total trading volume on that day [1][2] - The transaction price was 35.5 yuan per share, which is a discount of 7.74% compared to the market closing price of 38.48 yuan [1][2]